



(51) International Patent Classification:

A61K 47/68 (2017.01) C12N 7/00 (2006.01)
A61P 1/16 (2006.01) C12N 15/86 (2006.01)
C07K 16/28 (2006.01) A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2024/033793

(22) International Filing Date:

13 June 2024 (13.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/507,817 13 June 2023 (13.06.2023) US

(71) Applicant: INTERIUS BIOTHERAPEUTICS, INC.

[US/US]; 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US).

(72) Inventors: **BORAL, Debasish**; c/o Interius Biotherapeutics, Inc., 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US). **SCHNEPP, Bruce C.**; c/o Interius Biotherapeutics, Inc., 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US). **JOHNSON, Philip R.**; c/o Interius Biotherapeutics, Inc., 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US).

(74) Agent: **ZHANG, Clark et al.**; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: HEPATOCYTE TARGETING MOLECULES AND METHODS OF USE THEREOF




FIG. 1A

(57) Abstract: Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S₁, wherein T is a target binding domain that targets the viral particle to the liver and S₁ is a stalk portion. The stalk portion may comprise a variant Fc domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S₁ may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
08 May 2025 (08.05.2025)